Yes, Norditropin Treats Short Stature in Children
Norditropin (somatropin) is a recombinant human growth hormone approved by the FDA for treating short stature due to growth hormone deficiency (GHD) in children.[1] It helps children grow taller by mimicking the body's natural growth hormone, which stimulates bone and tissue growth. Treatment typically starts after confirming GHD through blood tests and growth monitoring.
How Norditropin Works for Short Stature
Norditropin is injected subcutaneously daily. In GHD-related short stature, it increases growth velocity—studies show children gaining 8-12 cm/year initially, tapering over time.[1][2] The FDA label specifies use until growth plates close or adult height is reached. It's also approved for idiopathic short stature (ISS), where no clear cause exists, but only if height is below the 1.2nd percentile and expected adult height is poor.[1]
Common Indications Beyond GHD Short Stature
- Turner syndrome: Short stature from chromosomal issues.
- Prader-Willi syndrome: Genetic disorder with poor growth.
- Small for gestational age (SGA): Children not growing well post-birth.[1]
Noonan syndrome short stature is another label, but approval varies by region.
Who Qualifies and Treatment Timeline
Pediatric endocrinologists diagnose via auxology (growth charts), IGF-1 levels, and stimulation tests. Treatment lasts 2-7 years, with monitoring every 3-6 months for height, side effects, and thyroid function.[2] Final height gains average 5-10 cm in GHD cases.[3]
Risks and Side Effects Patients Report
Common issues include injection-site pain, headaches, and fluid retention. Rare risks: scoliosis worsening, high blood sugar, or intracranial pressure. Long-term cancer risk is debated but not proven elevated in approved uses.[1][2] Annual cost runs $20,000-$50,000 USD, often covered by insurance for labeled indications.[4]
Alternatives to Norditropin
| Drug/Device | Key Difference | Approval for Short Stature |
|-------------|----------------|----------------------------|
| Genotropin (Pfizer) | Similar somatropin; pen device | Yes, GHD/ISS/Turner |
| Humatrope (Lilly) | Vial or pen; dosing flexibility | Yes, GHD/Noonan |
| Omnitrope (Sandoz) | Biosimilar; lower cost | Yes, GHD |
| Skytrofa (Ascendis) | Weekly injection | GHD only; less frequent dosing |
Switching depends on insurance, needle phobia, or adherence.[4]
Patent Status and Availability
Norditropin's core patents expired in the US by 2018, allowing biosimilars like Omnitrope.[5] Check DrugPatentWatch.com for latest expirations on delivery devices like FlexPro pens, some extending to 2028.[5]
[1]: FDA Label - Norditropin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020280s107lbl.pdf)
[2]: Pediatric Endocrine Society Guidelines (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114101/)
[3]: New England Journal of Medicine meta-analysis (https://www.nejm.org/doi/full/10.1056/NEJMoa1408020)
[4]: GoodRx pricing data (https://www.goodrx.com/norditropin)
[5]: DrugPatentWatch - Norditropin (https://www.drugpatentwatch.com/p/tradename/NORDITROPIN)